Synergy Pharmaceuticals is developing new drugs to treat gastrointestinal disorders and diseases. Plecanatide, the company’s lead proprietary drug candidate, functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in CIC patients. Synergy also initiated dosing of patients in a major Phase II/III clinical trial to treat chronic idiopathic constipation. Synergy’s second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel diseases. For more information visit the company’s Web site at: www.synergypharma.com.

Aegis Capital Corp. is a full service retail and institutional broker-dealer located in New York City. Aegis Capital’s management is committed to providing the highest level of service to its clients. The firm realizes this goal by running an independent, conflict-free platform that is focused on enhancing the goals of clients by bringing unencumbered advice, which enables them to freely create a plan centered on each client. For more information on Aegis Capital, visit www.aegiscapcorp.com.

Let us hear your thoughts below: